School of Life Science and Technology, Shanghai Jiao Tong University, Shanghai, 200240, PR China.
Virology. 2010 Nov 25;407(2):319-24. doi: 10.1016/j.virol.2010.08.007. Epub 2010 Sep 20.
Edible vaccines that can be made widely available and easily administered could bring great benefit to the worldwide battle against pandemic viral infections. They can be used not only for the vaccination of humans and domesticated animals, but also for wild herds and live stock which are otherwise difficult to vaccinate. In this study, we report the development of an edible mini-capsule form of live, non-persisting, recombinant Lactococcus lactis (L. lactis) vaccine against the highly virulent influenza H5N1 strain. Recombinant L. lactis-based H5N1 HA antigen expression constructs were made and shown to be able to induce higher levels of HA-specific serum IgG and fecal IgA antibody production after oral administration. The vectors were then formulated into a mini-capsule dosage form and fed to mouse. Four doses of oral administration rendered complete protection of the mouse against lethal challenges of H5N1 virus.
可广泛供应且易于管理的食用疫苗可能会给全球对抗大流行病毒感染的斗争带来巨大益处。它们不仅可用于人类和驯养动物的接种，也可用于难以接种的野生畜群和牲畜。在这项研究中，我们报告了一种可食用的迷你胶囊形式的活的、非持续存在的重组乳球菌（Lactococcus lactis，L. lactis）疫苗的开发，该疫苗可针对高毒力的 H5N1 流感株。构建了基于重组乳球菌的 H5N1 HA 抗原表达构建体，并证明口服后可诱导更高水平的 HA 特异性血清 IgG 和粪便 IgA 抗体产生。然后将载体制成迷你胶囊剂型并喂食给小鼠。四次口服给药可完全保护小鼠免受 H5N1 病毒的致命挑战。
